{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=88",
    "query": {
      "condition": "Safety Study",
      "page": 88
    },
    "page_size": 10
  },
  "pagination": {
    "page": 88,
    "page_size": 10,
    "total_count": 33600,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=89&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=87&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T20:51:02.636Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01304316",
      "title": "Dose-Escalation Safety and Pharmacokinetic Study of K305",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anesthesia"
      ],
      "interventions": [
        {
          "name": "Tetracaine HCl 3% and Oxymetazoline HCl 0.05%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Renatus, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2010-09",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2017-08-31",
      "last_synced_at": "2026-11-21T20:51:02.636Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01304316"
    },
    {
      "nct_id": "NCT01067521",
      "title": "A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Glatiramer acetate (GA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1404,
      "start_date": "2010-06-22",
      "completion_date": "2017-05-12",
      "has_results": true,
      "last_update_posted_date": "2021-12-09",
      "last_synced_at": "2026-11-21T20:51:02.636Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01067521"
    },
    {
      "nct_id": "NCT00189514",
      "title": "A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "pramlintide acetate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 210,
      "start_date": "2005-09",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-11",
      "last_synced_at": "2026-11-21T20:51:02.636Z",
      "location_count": 21,
      "location_summary": "Chula Vista, California • San Diego, California • Walnut Creek, California + 18 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00189514"
    },
    {
      "nct_id": "NCT00527904",
      "title": "A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Ulcer"
      ],
      "interventions": [
        {
          "name": "PN400 (VIMOVO)",
          "type": "DRUG"
        },
        {
          "name": "PN 400 (VIMOVO)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "POZEN",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 239,
      "start_date": "2007-03",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2010-08-31",
      "last_synced_at": "2026-11-21T20:51:02.636Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00527904"
    },
    {
      "nct_id": "NCT03574584",
      "title": "A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolism and Nutrition Disorders",
        "Overweight or Obesity"
      ],
      "interventions": [
        {
          "name": "NNC0165-1562",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (NNC0165-1562)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 37,
      "start_date": "2018-06-18",
      "completion_date": "2019-07-27",
      "has_results": false,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-11-21T20:51:02.636Z",
      "location_count": 2,
      "location_summary": "Tempe, Arizona • Lincoln, Nebraska",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03574584"
    },
    {
      "nct_id": "NCT00913133",
      "title": "Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thrombosis"
      ],
      "interventions": [
        {
          "name": "Desirudin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Canyon Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 516,
      "start_date": "2010-03",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2013-01-10",
      "last_synced_at": "2026-11-21T20:51:02.636Z",
      "location_count": 16,
      "location_summary": "Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 12 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00913133"
    },
    {
      "nct_id": "NCT02433652",
      "title": "Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "Recombinant live attenuated trivalent dengue vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rDEN2Δ30-7169 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2015-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-02-28",
      "last_synced_at": "2026-11-21T20:51:02.636Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02433652"
    },
    {
      "nct_id": "NCT00043147",
      "title": "Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "beclomethasone dipropionate",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "2002-04",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2013-05-30",
      "last_synced_at": "2026-11-21T20:51:02.636Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • New York, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00043147"
    },
    {
      "nct_id": "NCT03323749",
      "title": "A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Mitochondrial Myopathy"
      ],
      "interventions": [
        {
          "name": "elamipretide",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "placebo comparator",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "elamipretide open label treatment",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 218,
      "start_date": "2017-10-09",
      "completion_date": "2020-02-10",
      "has_results": true,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-11-21T20:51:02.636Z",
      "location_count": 13,
      "location_summary": "La Jolla, California • Palo Alto, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03323749"
    },
    {
      "nct_id": "NCT06485258",
      "title": "CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rotavirus Infections"
      ],
      "interventions": [
        {
          "name": "3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-08-06",
      "completion_date": "2026-02-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-11-21T20:51:02.636Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06485258"
    }
  ]
}